Article

Dr. Shore Provides an Overview of Biomarkers in Prostate Cancer

Author(s):

Neal D. Shore, MD, FACS

Neal D. Shore, MD, FACS, medical director, Carolina Urologic Research Center, provides an overview of biomarkers in prostate cancer.

Neal D. Shore, MD, FACS, medical director, Carolina Urologic Research Center, provides an overview of biomarkers in prostate cancer.

“The field of biomarkers in prostate cancer is exploding exponentially, and it has been for some time now,” Shore says. “The challenge is that most of the biomarkers that are commercially available are not reimbursed and, some might argue, are truly not yet ready for primetime.”

Newsletter

Stay up to date on cancer updates, research and education

Subscribe Now!
Related Videos
Daniel Jernazian, who beat cancer twice, credits his sports mindset for survival and calls it winning his ‘life World Championship’.
Patients in rural or underserved areas may have worse outcomes, highlighting the need for early support to address care access barriers.
Image of man with text.
Dr. Emre Yekedüz discusses how ASCO 2025 highlights precision medicine, biomarkers and the gut microbiome as keys to advancing kidney cancer care.
Dr. Breelyn Wilky stresses the importance of expert guidance and second opinions for patients with GIST, as treatment options continue to evolve rapidly.
Mark Daniels, 83, credits CAR T-cell therapy and compassionate care for helping him overcome lymphoma and endure the isolating treatment toll.
An early study of BGB-16673 for hard-to-treat leukemia found that side effects were manageable with no new safety concerns.
Image of woman with text.
Image of goy, and text.
Watch oncology dietitian Kenisha Parikh prepare creamy lentil soup, a soothing, protein-packed recipe to help ease side effects during treatment.
Related Content
Image of prostate model.
June 27th 2025

June Prostate Cancer Highlights: Top 5 Updates Patients Should Know

Ryan Scott
June brought major prostate cancer updates, and CURE is sharing the latest FDA approvals, label expansions, and emerging data on the role of AI in care.
Image of CURE's Cancer Horizons podcast logo: a white microphone with yellow noise lines. Highlights from the 2024 ASCO gastrointestinal and genitourinary cancer conferences.
January 30th 2024

Highlights from the Gastrointestinal and Genitourinary Cancer Conferences

Alex Biese Brielle Benyon
Here are some of the top stories from the recent Gastrointestinal Cancers Symposium as well as the Genitourinary Cancers Symposium.
Image of Dr. Ravi, with text,
June 26th 2025

Making Prostate Cancer Easier to Understand for Newly Diagnosed Patients

Ryan Scott
Dr. Ravi Munver explained that, for patients who are recently diagnosed with prostate cancer, it is important to explore treatment option with their care.
CURE Cancer Horizons podcast logo
January 29th 2024

Prostate Cancer Headlines, CAR-T Warnings and Laughter Therapy

Alex Biese Brielle Benyon
CURE® editors discuss last week’s biggest cancer headlines, from Dexter Scott King’s death to the potential of laughter therapy to boost quality of life.
Image of smiley face.
June 20th 2025

Radiation and Resilience: Laughing Through the Hardest Days

Dave Davison
It’s a bad day when a doctor says you have cancer. It’s a worse day when he says it’s stage prostate cancer with a metastatic lesion.
FDA approves updated labeling for Talzenna plus Xtandi in men with HRR gene-mutated metastatic prostate cancer: © stock.adobe.com.
June 19th 2025

FDA Updates Talzenna-Xtandi Label for HRR-Mutated Metastatic Prostate Cancer

Spencer Feldman
FDA approves updated labeling for Talzenna plus Xtandi in men with HRR gene-mutated metastatic prostate cancer, showing a 14-month survival benefit.